Author:
Giannelli Serena Gea,Luoni Mirko,Bellinazzi Benedetta,Iannielli Angelo,Middeldorp Jinte,Philippens Ingrid,Körbelin Jakob,Broccoli Vania
Abstract
SummaryAdeno-Associated Virus 9 (AAV9) is a delivery platform highly exploited to develop gene-based treatments for neurological disorders given its low pathogenicity and brain tissue tropism. However, the efficacy of this vector is dampened by its relatively low efficiency to cross the adult blood-brain barrier (BBB) and inherent targeting to the liver upon intravenous delivery. We generated a new peptide display library starting from a galactose binding-deficient AAV9 capsid and selected two new AAV9 engineered capsids, named AAV-Se1 and AAV-Se2, with an enhanced targeting in mouse and marmoset brains after intravenous delivery. Interestingly, the loss of the galactose binding strongly reduced the undesired targeting to peripheral organs, and above all liver, while not compromising the transduction of the brain vasculature. However, we had to reconstitute the galactose binding in order to efficiently infect non-endothelial brain cells. Thus, the combinatorial actions of the galactose-binding domain and the installed exogenous displayed peptide are crucial to enhance BBB crossing together with brain cell transduction. We also identified Ly6C1 as primary receptor for AAV-Se2 which is a Ly6A homologue highly expressed in the brain endothelial cells. This study describes a new strategy to select neurotropic AAV9 variants and identifies two novel capsids with high brain endothelial infectivity and extremely low liver targeting based on manipulating the AAV9 galactose binding domain.
Publisher
Cold Spring Harbor Laboratory